



## OUTLICENSING OPPORTUNITY

## Mixed Amphetamine Extended Release Capsules Bioequivalent to Adderall XR®

Product Overview and General Licensing Terms

### Delayed-release 12-h mixed amphetamine once-a-day capsules

dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate

**Indication**  
ADHD

**Reference Product**  
Adderall XR® (Shire)

**Strengths**  
5, 10, 15, 20, 25 and 30 mg

Bioequivalence to Adderall XR® demonstrated in fed and fasting conditions for D and R salts.

**Exclusivity**  
Single Canadian Licensee


### Stage of Development

## Ready to Transfer to Licensee Facility

Formulation Fully Proportional from 5 mg to 30 mg with Biphasic Release Profile

- Bioequivalence to Adderall XR® demonstrated in human trials
- Exhibit batch manufacturing completed
- Accelerated and long-term stability supporting 24-month shelf life on filing

Human PK versus Adderall XR® | Fasting conditions



### General terms

- Upfront Licensing Fee
- Development, Regulatory and Sales Milestones
- Royalties on Net Sales

### Next Steps

- Seeking Term-sheets from Interested Parties